Fondaparinux sodium promising in preventing major CV events in ACS

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1318, 2001-01, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fondaparinux Sodium

By Keam S.J.   Goa K.L.  

Drugs, Vol. 62, Iss. 11, 2002-01 ,pp. : 1673-1685

Adis International

Access to resources Recommend Favorite

Fondaparinux has the edge over enoxaparin in ACS

By  

Inpharma, Vol. 1, Iss. 1505, 2005-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Fondaparinux better than enoxaparin or UFH in ACS

By  

Inpharma, Vol. 1, Iss. 1557, 2006-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Fondaparinux Sodium: A Review of its Use in the Prevention of Venous Thromboembolism Following Major Orthopaedic Surgery

By Neil A. Reynolds   Caroline M. Perry   Lesley J. Scott  

Drugs, Vol. 64, Iss. 14, 2004-01 ,pp. : 1575-1596

Adis International

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous Thromboembolism: Use in Patients Undergoing Major Orthopaedic Surgery

By Sullivan S.D.  

PharmacoEconomics, Vol. 22, Iss. 9, 2004-01 ,pp. : 605-620

Adis International

Access to resources Recommend Favorite